newsfilter
← Latest News
Business Wire·

PhaseBio Announces Publication of Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab in NEJM Evidence

Results previously presented in a Late-Breaking Science Session at the American Heart Association's 2021 Scientific Sessions Global Phase 3 trial of bentracimab achieved both primary reversal endpoint and co-primary endpoint of clinical hemostasis